(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/207632 A1

(51) International Patent Classification:
A61K 39/00 (2006.01) *C07K 14/47* (2006.01)
A61P 35/00 (2006.01) *C07K 14/52* (2006.01)

(21) International Application Number:
PCT/US2025/021343

(22) International Filing Date:
25 March 2025 (25.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/569,841 26 March 2024 (26.03.2024) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **BJØRKLUND, Sunniva**; c/o Nykode Therapeutics ASA, Gaustadalléen 21, 0349 Oslo (NO). **DEERING, Raquel**; 140 Silver Spring Road, Ridgefield, Connecticut 06877 (US). **DILLARD, Pierre**; c/o Nykode Therapeutics ASA, Gaustadalléen 21, 0349 Oslo (NO). **FLAMAR, Anne Laure**; c/o Nykode Therapeutics ASA, Gaustadalléen 21, 0349 Oslo (NO). **HANSEN, Johanna**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **KUHNERT, Frank**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **LIN, Chia-Yang**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **NORELL, Håkan**; c/o Nykode Therapeutics ASA, Gaustadalléen 21, 0349 Oslo (NO). **PAWARIA, Sudesh**; 47 Siwanoy Blvd, Eastchester, New York 10709 (US). **THURSTON, O. Gavin**; 74 Rudd Pond Road, Millerton, New York 12546 (US). **VAN METER, Michael**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **WOLD, Christian Winther**; c/o Nykode Therapeutics ASA, Gaustadalléen 21, 0349 Oslo (NO).

(74) Agent: **CANDE, Jessica, D.** et al.; Fenwick & West LLP, 801 California Street, Mountain View, CA 94041 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS



FIG. 4

(57) Abstract: Nucleic acids encoding recombinant fusion proteins directed to calreticulin are described, as well as pharmaceutical compositions comprising such nucleic acids and therapeutic methods using such nucleic acids and pharmaceutical compositions, such as for treating cancer.

[Continued on next page]

WO 2025/207632 A1

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*